MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY
申请人:McElroy John F.
公开号:US20080182824A1
公开(公告)日:2008-07-31
The invention provides novel N-benzyl-N-propargyl-amines that are monoamine oxidase inhibitors, but generally exhibit little or no CNS effects.
US8124802B2
申请人:——
公开号:US8124802B2
公开(公告)日:2012-02-28
[EN] MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY<br/>[FR] N-BENZYL-N-PROPARGYL-AMINES INHIBANT LA MAO UTILES POUR TRAITER L'OBÉSITÉ
申请人:JENRIN DISCOVERY
公开号:WO2008092091A2
公开(公告)日:2008-07-31
[EN] The invention provides novel N-benzyl-N-propargyl-amines that are monoamine oxidase inhibitors, but generally exhibit little or no CNS effects. [FR] L'invention concerne de nouvelles N-benzyl-N-propargyl-amines qui agissent comme inhibiteurs de la monoamine oxydase, mais dont les effets sur le SNC sont généralement faibles ou nuls.
Activity-Based Probes for Studying the Activity of Flavin-Dependent Oxidases and for the Protein Target Profiling of Monoamine Oxidase Inhibitors
作者:Joanna M. Krysiak、Johannes Kreuzer、Peter Macheroux、Albin Hermetter、Stephan A. Sieber、Rolf Breinbauer
DOI:10.1002/anie.201201955
日期:2012.7.9
High profile: New activity‐based protein profiling (ABPP) probes have been designed that target exclusively monoamine oxidases A and B within living cells (see picture; FAD=flavin adenine dinucleotide, FMN=flavin monodinucleotide). With these probes it could be shown that the MAO inhibitor deprenyl, which is in clinical use against Parkinson's disease, shows unique protein specificity despite its covalent
高调:设计了新的基于活性的蛋白质分析 (ABPP) 探针,专门针对活细胞内的单胺氧化酶 A 和 B(见图;FAD=黄素腺嘌呤二核苷酸,FMN=黄素单二核苷酸)。通过这些探针,可以证明 MAO 抑制剂 deprenyl 已在临床上用于治疗帕金森病,尽管其作用机制是共价的,但仍显示出独特的蛋白质特异性。